BioCryst Forecasts Fiscal Year 2024 Orladeyo Net Revenue Of $380M-$400M, The Company Expects Operating Profit In 2024, Approaching Positive Eps And Positive Cash Flow In 2H 2025
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals forecasts its fiscal year 2024 net revenue for Orladeyo to be between $380M-$400M. The company anticipates operating profit in 2024, with expectations of approaching positive EPS and achieving positive cash flow in the second half of 2025.
February 26, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharmaceuticals projects significant revenue growth for Orladeyo in FY2024, with anticipated operating profit and positive financial milestones in the near future.
The forecasted increase in net revenue for Orladeyo suggests strong sales performance and market acceptance, likely leading to investor optimism. The anticipation of operating profit and positive EPS indicates improving financial health, which could positively impact stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100